| Name | Title | Contact Details |
|---|
Ridgeview’s earliest beginnings date back to 1954 when at the suggestion of the Oak Ridge schools’ Pupil Personnel Department, under the leadership of Ms.Sarah Ketron, a group of Oak Ridge and Anderson County citizens met to consider forming a mental h...
Honson Industries Ltd is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Called TICO, our strategy is focused on developing and selling pharmaceutical products in the Topical, Injectable, Complex and Ophthalmic markets. Based in Buena, New Jersey, we have approximately 200 employees working at our 33,000 square-foot manufacturing and R&D complex, as well as in our Canada and Estonia operations. We are currently expanding our New Jersey site to include a sterile injectable, isolator-based manufacturing suite and an expanded footprint for the production of our topical products. There are three pillars that shape our company. First, we are driven by impactful science. Second, we accept no middle ground when it comes to product quality. Finally, we believe in fostering a career of craftsmanship, where our people can become experts in their trade. The spirit of our culture is to work hard, and be nice to people.
REDCON1 is a company that creates premium nutritional supplements for athletes of all levels, with the objective of bringing them to the highest state of readiness.
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.